Skip to content

Effect of Lactoferrin in Pneumonia Treatment

Efficacy of Lactoferrin as Adjunct Therapy for Pneumonia in Children and Adolescents

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05431023
Enrollment
72
Registered
2022-06-24
Start date
2022-08-01
Completion date
2024-08-01
Last updated
2022-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia

Brief summary

Pneumonia is defind as the inflammation of lung tissue caused by an infectious agent that results in acute respiratory signs and symptoms. Community acquired pneumonia (CAP) is a major cause of morbidity and increased health care costs. In developing nations, pneumonia remains a significant cause of mortality in children. Pneumonia occurs in 30 to 45 of every 1,000 children under 5 years of age; it is less common in 5- to 9-year olds (16 to 22/1,000) and in older children (7 to 16/1,000). Streptococcus pneumoniae is the primary bacterial cause of pneumonia in infants and children. Viral etiologies become less prevalent and mycoplasmal and chlamydial infections become more prevalent with increasing age

Detailed description

Lactoferrin (LF) is iron-binding glycoprotein of the transferrin family that is expressed and secreted by glandular cells and is found in most body fluids . It appears at especially high concentrations in mammalian milk and was first identified in bovine milk , and was subsequently isolated from human milk. LFs bacteriostatic function is due to its ability to take up the Fe3+ ion, limiting use of this nutrient by bacteria at the infection site and inhibiting the growth of these microorganisms as well as the expression of their virulence factors .

Interventions

DRUGLactoferrin

Lactoferrin binds to and blocks glycosaminoglycan viral receptors, especially heparan sulfate (HS). The binding of LF and HS prevents the first contact between virus and host cell and therefore prevents the infection

DRUGPneumonia treatment

Antibiotics for pneumonia

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
1 Months to 18 Years
Healthy volunteers
No

Inclusion criteria

* Pneumonia patients * from the age of one month to the age of 18 years .

Exclusion criteria

Neonates and any children with : * immune deficiency * congenital heart disease * neuromascular disorder * genetic syndromes

Design outcomes

Primary

MeasureTime frameDescription
Survival rate.Up to 8 weeksComparing the influence of the intervention on the Survival rate.

Secondary

MeasureTime frameDescription
Mean change in the disease severity (clinical assessment)Up to 4 weeksRecording the changes from severe to moderate or mild and the time taken

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026